Activation of both the canonical and non-canonical WNT cascades has been reported in localized and advanced prostate cancer, and oncogenic deregulation of core WNT pathway components frequently occurs in primary and metastatic prostate cancer (up to 6% and 19% incidence respectively [45]), primarily via APC deep deletion/truncating mutations and CTNNB1/β-catenin activating mutations [45,46,320,322,323]. This evidence concerns the gene APC and prostate cancer.